I was born, bred and began my Urology training in New Zealand before moving to Cambridge to complete a Fellowship in Uro-oncology in 2003. I have been a Consultant Urologist at Addenbrookes since 2004 and specialise in Holmium Laser Enucleation of the Prostate (which I learned from the urologists in NZ who developed it), Urolift. Rezum and kidney surgery. I have the largest HoLEP experience in the UK having performed more than 2,700 cases and currently perform over 300 cases per year. I also work at the Princess Grace Hospital, London, and the Cambridge Nuffield and Spire Hospitals.
Selected publications from PubMed
Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised (13)C-MRI and mass spectrometry imaging.
Horvat-Menih I, Casey R, Denholm J, Hamm G, Hulme H, Gallon J, Khan AS, Kaggie J, Gill AB, Priest AN, Duarte JAG, Yong C, Brodie C, Whitworth J, Barry ST, Goodwin RJA, Anand S, Dodd M, Honan K, Welsh SJ, Warren AY, Aho T, Stewart GD, Mitchell TJ, McLean MA, Gallagher FA
Commun Med (Lond). 2026 Jan 13;6(1):108 doi: 10.1038/s43856-025-01371-y.
Applied trigonometry in elucidating the mechanism of post-HoLEP urinary incontinence.
Schwartztuch Gildor O, Mendelson T, Gomez Sancha F, Herrmann TR, Scoffone C, Aho T, Lusuardi L, de Figueiredo FCA, Aviram G, Nevo A, Yossepowitch O, Sofer M
World J Urol. 2025 Dec 4;44(1):19 doi: 10.1007/s00345-025-05943-4.
A rare case of inflammatory myofibroblastic tumour mimicking retained prostatic tissue following HoLEP.
Yun JW, Ali MK, Anderson C, Aho T, El-Husseiny T
Urol Case Rep. 2025 Sep;62:103135 doi: 10.1016/j.eucr.2025.103135.
Should magnetic resonance imaging be considered in every patient before a bladder outflow obstruction procedure?
Donkov I, Chatzikrachtis N, Chatterjee A, Aho T, Emberton M, Nikolinakos P
Arch Ital Urol Androl. 2025 Jun 30;97(2):13935 doi: 10.4081/aiua.2025.13935.
Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH.
Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Kaufman RP Jr, Badlani G, Plante M, Desai M, Doumanian L, Te AE, Roehrborn CG
Can J Urol. 2022 Feb;29(1):10960-10968.
Dr. Bhaskar Somani, Dr. Khurshid Ghani, Dr. Amy E. Krambeck and Dr. Tev Aho present "Improving Endourology Practices With Innovating Technologies Using State-of-the-art Holmium Lasers".
With Lumenis
Published
Oct 2020
Clinical Case BPH refers to a pathological enlargement of the prostate gland. It is a very common disease affecting men over 50 years-old, with a prevalence of 90% in those over 80 years-old. The causes are no clear, but hormone changes are thought to play a role. Patients with BPH may present with symptoms that vary from mild to severe, and are commonly referred as low obstructive urinary symptoms (weak urinary flow, nocturia, frequent urination, urgency, etc.). In this lecture Dr. Tev Aho explains us the evolution of BPH treatment, the many options available and how can we tailor the treatment options to the patient, putting him first.
Published
Oct 2020
The holmium laser was one of the first energy sources used to perform anatomical endoscopic enucleation of the prostate (AEEP). The term AEEP refers to total enucleation of the BPH component of the prostate in a similar fashion to open simple prostatectomy. Total adenomectomy results in maximal disobstruction of the prostate.
With Boston Scientific
Published
Nov 2018
Help your network discover Dr. Tevita Aho's clinical expertise.
